期刊
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
卷 109, 期 38, 页码 15502-15507出版社
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1206446109
关键词
dementia; low-density lipoprotein-related protein 1; peripheral; in vivo microdialysis; sequestration
资金
- National Institutes of Health [AG13956, NS034467, AG034004, NS34467, AG023084, AG029481, P30-NS057105]
- Eli Lilly
- Pfizer
The apolipoprotein E (APOE)-epsilon 4 allele is the strongest genetic risk factor for late-onset, sporadic Alzheimer's disease, likely increasing risk by altering amyloid-beta (A beta) accumulation. We recently demonstrated that the low-density lipoprotein receptor (LDLR) is a major apoE receptor in the brain that strongly regulates amyloid plaque deposition. In the current study, we sought to understand the mechanism by which LDLR regulates A beta accumulation by altering A beta clearance from brain interstitial fluid. We hypothesized that increasing LDLR levels enhances blood-brain barrier-mediated A beta clearance, thus leading to reduced A beta accumulation. Using the brain A beta efflux index method, we found that blood-brain barrier-mediated clearance of exogenously administered A beta is enhanced with LDLR overexpression. We next developed a method to directly assess the elimination of centrally derived, endogenous A beta into the plasma of mice using an anti-A beta antibody that prevents degradation of plasma A beta, allowing its rate of appearance from the brain to be measured. Using this plasma A beta accumulation technique, we found that LDLR overexpression enhances brain-to-blood A beta transport. Together, our results suggest a unique mechanism by which LDLR regulates brain-to-blood A beta clearance, which may serve as a useful therapeutic avenue in targeting A beta clearance from the brain.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据